Stem cells used to enhance immune response to HIV in primates
In non-human primates, researchers have found that mesenchymal stem cells were effective at strengthening the immune response to HIV.
List view / Grid view
In non-human primates, researchers have found that mesenchymal stem cells were effective at strengthening the immune response to HIV.
Monoamine oxidase inhibitors can block the function of a protein, helping T cells to effectively fight cancer, a study in mice has shown.
Researchers have found a protein that, when inhibited in mice with cancer, increased the response to immunotherapy.
Chimeric antigen receptor (CAR) T and natural killer (NK) therapies may become the future of cancer treatment. Dr Jim Ross explains how bioelectronic assays are a non-invasive, label-free approach built for real-time, dynamic assessment of cell therapy potency.
A team has demonstrated in mouse models that a self-assembling nanofibre material could limit the damage caused by cytokines in inflammatory diseases.
In this article, Dr Lien Lybaert describes how the innate and adaptive immune system work together to produce an effective and durable antitumour response. She explains why the best strategy for personalised cancer therapy is therefore to identify major histocompatibility (MHC) binding epitopes to cover the full antigenic repertoire of…
In this Q&A, Dr Taha Merghoub discusses how a combination of glycolytic-pathway inhibition and immune checkpoint blockade using anti-CTLA-4 in patients with highly glycolytic tumours could present a personalised approach for immuno-oncology.
Recent years have seen an increase in the development of biomaterial and nanoparticle-based vaccine formulations. Sushma Kumari, Sonal Asthana and Kaushik Chatterjee from the Department of Materials Engineering at the Indian Institute of Science discuss why these materials have such high potential in the fight against infectious diseases.
Researchers have revealed that T cells in blood samples from people who recovered from COVID-19 responded to SARS-CoV-2 variants.
Researchers have developed a CAR T-cell engineering technique to ensure that only cancer cells are targeted, leaving healthy cells alone in solid tumours.
Researchers have found that mutations in SARS-CoV-2 T cell epitopes enable the virus to evade the immune response of killer T cells.
A team has used two viruses to administer specific tumour components in mice with cancer to stimulate their immune system.
A new study has suggested that asymptomatic individuals with COVID-19 mount an efficient T-cell response that protects the host.
Researchers have shown that inhibiting Treg activation in tumours can provide effective immune responses without autoimmune toxicity.
A new MVA-based vaccine has shown success at inducing COVID-19 antibody and T-cell responses in pre-clinical studies.